Emerging Therapeutic Strategies of Different Immunotherapy Approaches Combined with PD-1/PD-L1 Blockade in Cervical Cancer
DOI: https://doi.org/10.2147/DDDT.S374672
2022-09-09
Abstract:Yanjun Ge, 1, &ast Yuchen Zhang, 1, &ast Kong-Nan Zhao, 2, 3 Haiyan Zhu 1, 2 1 Department of Gynecology, Shanghai First Maternity and Infant Hospital, Tongji University School of Medicine, Shanghai, People's Republic of China; 2 School of Basic Medical Science, Wenzhou Medical University, Wenzhou, People's Republic of China; 3 Australian Institute for Bioengineering and Nanotechnology, The University of Queensland, St Lucia, Queensland, Australia &astThese authors contributed equally to this work Correspondence: Haiyan Zhu, Shanghai First Maternity and Infant Hospital, No. 2699 Gaokexi Road, Shanghai, 200092, People's Republic of China, Tel +86 13758465255, Email Currently, therapeutic methods for advanced and recurrent cervical cancer patients are limited and unsatisfactory. Immunotherapy is a promising approach for cancer treatment. However, its investigation and application in cervical cancer remain slow. Although pembrolizumab is a remarkable milestone as the first anti-PD-1 mAb approved by the FDA for treating cervical cancer, it shows relatively low response rate. It is noticed that multiple novel immune checkpoints have emerged in recent years, such as CTLA-4, TIGIT, LAG-3, TIM-3, and A2AR. Accumulated studies have suggested that strategies combining the PD-1/PD-L1 inhibitors and different immunotherapies or biotherapies could enhance the antitumor efficacy in human cancers. In this review article, we provide an overview of anti-PD-1/PD-L1-based immunotherapy in cervical cancer treatment. We further summarize the developmental strategies of different immunotherapies or biotherapies combined with PD-1/PD-L1 blockade for treating cervical cancer. We also discuss how these new combined therapies increase the therapeutic benefit gained from experimental evidence in cervical cancer. Keywords: cervical cancer, immunotherapy, PD-1/PD-L1, combinatorial strategy, mechanism, clinical practice Cervical cancer (CC) ranks fourth for both incidence and mortality among cancers in women globally, 1 indicating that this cancer remains a heavy burden worldwide despite the development and application of prophylactic HPV vaccines and effective screening and early detection methods. Traditional treatments for cervical cancer are surgery, radiation therapy, and chemotherapy. 2 For early-stage cervical cancers, radical surgery and radiation therapy can achieve good prognosis. However, for advanced and recurrent cervical cancers, the efficacy of the current treatment modalities is unsatisfactory, resulting in poor survival outcomes. 3 Therefore, searching for novel treatment strategies for advanced and recurrent cervical cancers is necessary. Treatments targeting epidermal growth factor receptor (EGFR) or vascular endothelial growth factor (VEGF) are improvements made in cervical cancer therapy in recent years. 4,5 But their efficacy is not very satisfying. Chemotherapy combined with the anti-VEGF antibody bevacizumab for cervical cancer showed progression-free survival of only 8.2 months in the phase III randomized trial, GOG 240. 6 Immunotherapy is emerging and rapidly developing in recent years. It is expected to harness the host's immune system to attack tumor cells by stimulating the adaptive immune system through the administration of anti-cancer vaccines, which is known as active immunotherapy, or by using immune compounds such as adoptive cellular transfer (ACT), immune checkpoint inhibitors (ICIs) and cytokines to enhance antitumor immunity, ie passive immunotherapy. 7,8 In addition, several other agents such as IDO (indoleamine 2.3-dioxygenase) inhibitors are classified as "immunomodulation", and they also enhance antitumor immune response through different mechanisms. 8 Compared with conventional treatment methods, immunotherapy demonstrates a more durable clinical response once effective, and is better tolerated. In particular, immune checkpoint inhibitors (ICIs) have made a remarkable step forward in the field of cancer immunotherapy. ICIs are used to block negative immune cell regulatory axes, such as programmed cell death-1 (PD-1) and its ligand PD-L1, which typically impair antitumor immunity when they are activated, aiming to restore the anti-cancer capacity of immune cells. It has been observed that PD-1 blockade induces antitumor responses through enhancing the activity of effector T cells and NK cells in tissues and tumor microenvironments and diminishing the number and suppressive activity of Treg cells, as well as abrogating the inhibition of kinases and recruitment of tyrosine phosphatases that are related to T cell activation. 9,10 Pembrolizumab, one of the ICIs, was approved by the F -Abstract Truncated-